NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES A PROSPECTUS, REGISTRATION OR OTHER MEASURES OTHER THAN THOSE REQUIRED BY SWEDISH LAW, IS PROHIBITED, OR OTHERWISE CONTRAVENES APPLICABLE RULES IN SUCH JURISDICTION OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURE. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

NANOLOGICA PUBLISHES INFORMATION DOCUMENT REGARDING RIGHTS ISSUE OF UNITS

Nanologica AB (publ) ("Nanologica" or the "Company") publishes information documents in relation to the rights issue of units of approximately SEK 110.5 million, before issue costs, resolved by the Board of Directors on 23 October 2026 based on the authorization granted by the Annual General Meeting on 21 May 2026 (the "Rights Issue"). The information document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website.

The information document
In connection with the Rights Issue, the Company has prepared an information document (the "**Information Document**") in accordance with Article 1.4 db and Article 1.5 (ba) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "**Prospectus Regulation**"). The Information Document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation.

Nanologica today announces that the Information Document has been registered with the Swedish Financial Supervisory Authority and is available on the Company's website, www.nanologica.com and on Bergs Securities AB's website, www. bergssecurities.se. Application forms for subscription without preferential rights will be available on Bergs Securities AB's website.

Timetable for the Rights Issue

2 november 2026	Publication of the Information Document
3 – 17 november 2026	Subscription period for the Rights Issue
3 – 12 november 2026	Trading in unit rights
3 November – 1 December 2026	Trading with BTU (Paid Subscribed Unit)
Around November 19, 2026	Announcement of the outcome of the Rights Issue

Advisors
Nanologica has engaged Redeye AB, Bergs Securities AB and Navia Corporate Finance AB as Joint Bookrunners, as well as Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue. Bergs Securities AB is also acting as issuing agent in connection with the Rights Issue.

Important information

The publication, publication or distribution of this press release may be subject to restrictions by law in certain jurisdictions and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with applicable rules in their respective jurisdictions. This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful. In a member state of the European Economic Area ("EEA"), securities referred to in this press release may only be offered in accordance with applicable exemptions in the Prospectus Regulation.

This press release does not constitute an offer or solicitation of any offer to buy or subscribe for any securities in the United States. The securities referred to herein may not be sold in the United States absent registration, or without the application of an exemption from registration, under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration, an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offer of such securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Japan, Canada, Hong Kong, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such release, publication or distribution of this information would be in violation of applicable rules or where such action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

This press release is not a prospectus within the meaning of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Rights Issue. In each member state of the EEA, this press release is only directed at "qualified investors" in that member state as defined in the Prospectus Regulation. This press release does not identify or purport to identify risks (direct or indirect) that may be associated with an investment in shares/units. An investment decision to acquire or subscribe for units in the Rights Issue may only be made based on publicly available information.

This press release contains forward-looking statements that relate to the Company's intentions, judgments or expectations regarding the Company's future results, financial condition, liquidity, development, prospects, expected growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the fact that they contain expressions such as "believes", "estimates", "anticipates", "intends", "estimates", "will", "may", "assumes", "should", "could" and, in each case, the negatives thereof, or similar expressions. Forward-looking statements should not be considered to be forecasts. The forward-looking statements in this press release are based on various assumptions, several of which are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no

assurance that they will occur or that they are correct. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes may, for a variety of reasons, differ materially from those set forth in the forward-looking statements. Such risks, uncertainties, contingencies and other material factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are accurate and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or publicly release any revisions to any forward-looking statements to reflect events that occur or circumstances that arise with respect to the content of this press release, unless required by law or applicable stock exchange rules.

For further information, please contact

Johanna Westerberg
Director IR, Communications and Marketing
johanna.westerberg@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science group that offers advanced solutions for the development, manufacture and purification of pharmaceuticals. By combining expertise in materials science, nanotechnology and chemical process development with contract development and manufacturing services, Nanologica supports the value chain from early development to commercial production of pharmaceuticals. The Group has particular strength in complex molecules and peptide-based drugs. The Group has appx. 70 employees and is headquartered in Södertälje, Sweden. Nanologica's share (ticker: NICA) has been listed on Nasdaq Stockholm's main market since 2022. For more information, please visit www.nanologica.com.

Attachments

NANOLOGICA PUBLISHES INFORMATION DOCUMENT REGARDING RIGHTS ISSUE OF UNITS
Informationsdokument (Bilaga IX), 2026 11 02